EVALUATION OF SAFETY AND IMMUNOGENICITY OF INACTIVATED WHOLE CULTURE CCPP TRIAL VCCINE IN NATIONAL VETERINARY INSTITUTE, BISHOFTU, ETHIOPIA

dc.contributor.advisorDr. Bedaso Mamo, Dr. Hundera Sori
dc.contributor.authorTakele, Tesgera
dc.date.accessioned2020-06-26T10:41:56Z
dc.date.accessioned2023-11-08T11:38:13Z
dc.date.available2020-06-26T10:41:56Z
dc.date.available2023-11-08T11:38:13Z
dc.date.issued2015-06
dc.descriptionMSc Thesisen_US
dc.description.abstractContagious caprine pleuropneumonia (CCPP) is a severe disease of goats occurring in many countries in Africa and Asia. It has been causing loss to Ethiopian goats contributing to the expansion of poverty of goat rearing society. In Ethiopia the inactivated CCPP vaccine has been produced and used. However, the vaccine produced by the institute could not satisfy the domestic demand let alone the foreign country demand. The nature of the seed strain, and the length of CCPP vaccine production process involving centrifugation and concentration which has time cost and involve expensive equipments has constrained the vaccine demand in NVI. As the result, the production technique which bypasses such lengthy production process and increase the vaccine yield per annual is mandatory. This study aimed to evaluate the safety and immunogenicity of whole culture CCPP trial vaccine which was produced by bypassing the lengthy centrifugation or concentration process. After the vaccine was produced its safety was confirmed and Mccp antibody free goats were grouped in to three and vaccinated and antibody level were evaluated by c-ELISA for eight weeks duration. The data obtained from safety and immunogenicity test results were analyzed by independent sample t-test and ANOVA by considering confidence interval of 95% and desired level of significance of 0.05. During comparison of safety tested and percent positive results, significance difference was not observed (p>0.05) but Comparison of the mean percent inhibition between whole culture vaccinated (61.52±2.92), positive control vaccinated (51.86±4.95) and negative control (40.65±2.84) showed presence of significant difference p<0.05 between the three groups. It was also seen that the serum antibody started to appear from seven days post-vaccination and continued for two months observation period. After 21 days the antibody level reached peak and remained peak until 8 weeks. The protectiveness of such peak antibody level should be checked by challenge test.en_US
dc.identifier.urihttp://etd.aau.edu.et/handle/123456789/21872
dc.language.isoenen_US
dc.subjectAntibodyen_US
dc.subjectc-ELISAen_US
dc.subjectContagious caprine pleuropneumoniaen_US
dc.subjectGoatsen_US
dc.subjectImmunogenicityen_US
dc.titleEVALUATION OF SAFETY AND IMMUNOGENICITY OF INACTIVATED WHOLE CULTURE CCPP TRIAL VCCINE IN NATIONAL VETERINARY INSTITUTE, BISHOFTU, ETHIOPIAen_US
dc.typeThesisen_US

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Takele Tesgera.pdf
Size:
941.95 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description: